Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Year end trading update

19 Jan 2009 07:00

RNS Number : 8037L
Cello Group plc
19 January 2009
 



19 January 2009

  

Cello Group plc

Year end trading update

 

Cello Group plc ("Cello" or the "Group", AIM: CLL), the leading independent market research and consulting group, today provides the following trading update for the year ended 31 December 2008

 

Since the announcement of the Group's interim results in early September, trading has tightened across certain sectors of Cello's broad domestic and international client base As a result, the Board anticipates that the Group's results for the full year will be at the lower end of market expectations.

There has been very strong cash conversion in the second half of 2008, as a result of which the Board expects to report year end net debt of less than £10.5m, significantly below consensus expectations.

The Group has agreed enlarged banking facilities with the revolving credit facility now increased from £18.0m to £20.0m for 2009, amortising to £17.0m for 2010. The overdraft facility of £2.0m has also been renewed and is now a multi-currency arrangement. The extra interest cost associated with these changes is expected to be broadly offset by lower overall interest rates.

The Group has re-estimated its total anticipated earn out obligations. These are now expected to be £15.2m compared with a previous estimate of £19.2m, with a minimum loan note component of £6.3m and the balance of £8.9m payable in shares. £7.8m of this total is anticipated to be settled in May 2009 with £3.2m payable in loan notes and £4.6m payable in shares. The balance of the total earn out commitment is payable between 2010 and 2013, with a loan note payment of £0.6m expected to be paid in 2010. The Group is entitled to pay an increased proportion of these total obligations in loan notes.

As well as the strong operating cash position and the reduced earn out provisions, the Group has continued to prudently reduce its cost base. In total over £2.0m of staff costs, on an annualised basis, have been removed during 2008.

Allan Rich, whose appointment as Acting Non-Executive Chairman was announced on September 2008has been confirmed as Non-Executive Chairman. Allan brings with him a wealth of experience of managing successfully through economic downturns.

 

The Group remains realistically cautious about the current outlook. While it is too early to give detailed guidance, numerous clients have indicated their intention to maintain their expenditure levels and the Group is seeing refreshed levels of spend from several of its public sector clients. In addition, all of Cello's investment start-up businesses are now trading profitably. All these factors, including the Group's strong financial position, should hold the Group in good stead in the current economic environment.

 

Cello expects to announce its preliminary results for the year ended 31 December 2008 on Tuesday 17 March 2009.

 

Enquiries

 

Cello Group 

 

Mark ScottChief Executive

020 7812 8460

Mark Bentley, Finance Director

 

Singer Capital Markets

 

Nicholas How

020 3205 7620

 

 

College Hill

 

Adrian Duffield/Rozi Morris

020 7457 2020

 

 

Notes to Editors (www.cellogroup.co.uk)

 

Cello is a market research and consulting group that listed on AIM in November 2004.

 

The Group's strategy is to create value for shareholders by building a world class market research business and a leading direct response business.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGUUACGUPBGAQ
Date   Source Headline
22nd Jan 20157:00 amRNSPRE-CLOSE TRADING STATEMENT
16th Jan 20155:15 pmRNSBlocklisting Interim Review
6th Jan 20154:50 pmRNSTotal Voting Rights
9th Dec 20147:00 amRNSAcquisition of Worldwide Promedica Inc
28th Nov 20141:10 pmRNSTotal Voting Rights
3rd Nov 201410:58 amRNSTotal Voting Rights
2nd Oct 201410:59 amRNSDirector/PDMR Shareholding
1st Oct 20141:05 pmRNSTotal Voting Rights
19th Sep 20144:10 pmRNSDirector/PDMR Shareholding
17th Sep 20147:00 amRNSInterim Results
1st Sep 20147:00 amRNSHolding(s) in Company
29th Aug 20147:00 amRNSTotal Voting Rights
31st Jul 20147:00 amRNSTotal Voting Rights
17th Jul 20147:00 amRNSTrading Update
1st Jul 20143:54 pmRNSBlocklisting Interim Review
1st Jul 201412:24 pmRNSTotal Voting Rights
25th Jun 20141:27 pmRNSIssue of Equity
18th Jun 20147:00 amRNSDirector/PDMR Shareholding
3rd Jun 20142:02 pmRNSDirector/PDMR Shareholding
30th May 20147:00 amRNSTotal Voting Rights
13th May 20141:00 pmRNSResults of Annual General Meeting
13th May 20147:00 amRNSAGM STATEMENT
13th May 20147:00 amRNSAcquisition of iS Healthcare Dynamics
8th May 20147:00 amRNSAdditional listing/TVR
30th Apr 20143:25 pmRNSTotal Voting Rights
25th Apr 20147:00 amRNSAcquisition of Line Digital
14th Apr 201412:17 pmRNSAnnual Report & Accounts 2013 & Notice of AGM
31st Mar 20147:00 amRNSTotal Voting Rights
20th Mar 20147:00 amRNSPreliminary Results for the Year Ended 31 Dec 2013
28th Feb 20147:00 amRNSTotal Voting Rights
3rd Feb 20147:00 amRNSTotal Voting Rights
22nd Jan 20147:00 amRNSPRE-CLOSE TRADING UPDATE
7th Jan 20142:17 pmRNSBlocklisting Interim Review
17th Oct 201310:53 amRNSDirector/PDMR Shareholding
11th Oct 201311:36 amRNSTransaction in Own Shares
11th Oct 20137:00 amRNSDirector/PDMR Shareholding
1st Oct 20132:58 pmRNSTotal Voting Rights
27th Sep 201311:42 amRNSDirector/PDMR Shareholding
19th Sep 20137:00 amRNSDirector/PDMR Shareholding
18th Sep 20137:00 amRNSInterim Results
13th Sep 201312:07 pmRNSIssue of Equity
17th Jul 20137:00 amRNSTrading update
8th Jul 201312:26 pmRNSTransaction in Own Shares
4th Jul 201310:00 amRNSDirector/PDMR Shareholding
14th Jun 20137:00 amRNSBlock Listing Application
3rd Jun 20133:12 pmRNSDirector/PDMR Shareholding
31st May 20139:00 amRNSTotal Voting Rights
21st May 201312:53 pmRNSDirector/PDMR Shareholding
15th May 201312:12 pmRNSHolding(s) in Company
14th May 20132:49 pmRNSResults of Annual General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.